ABOUT US

Amarin Technologies is a duly organized Argentinean company settled in Buenos Aires, engaged in the development and formulation of topical and transdermal pharmaceutical products using its proprietary drug delivery technologies and know-how in order to offer both innovative formulations of well-established drugs or generic versions of marketed products.

With R&D, manufacturing, and clinical research capabilities, we own a 1200 sqm state-of-the-art manufacturing plant for transdermal systems involving all operations (mixing, coating, slitting, cutting, pouching and labelling), where our experienced team coordinates and manages the project planning and the product development programs. This plant allows us to have enough flexibility to manufacture from pilot GMP batches (i.e. to supply any clinical study needs) to commercial-scale batches.

We also possess modern formulation and analytical laboratories, which work following cGMP and GLP guidelines. R&D activities are rendered by a qualified team including Pharmacists, Chemists, Statisticians and university students.

In addition, we may also perform pre-clinical and BA/BE clinical studies in accordance with GLP and GCP guidelines, offering other companies study monitoring and statistical analysis services, as well as the organization of full clinical programs.

1986
1986

Amarin is an Argentine company established in the City of Buenos Aires

1990
1990

Estradiol TDS licensed and supplied to Wyeth Ayerst in Latam for more than 10 years

1999
1999

TDS Technology Transfer to Indian Company Zydus Cadila

2000
2000

Fentanyl Patch developed by Amarin

2007
2007

Fentanyl exports from Argentina to EU began

2010
2010

Helm AG became a shareholder and marketing agent for Amarin

2011
2011

Formulations and manufacturing of fentanyl patch transferred to EU (LTS & IBSA)

2016
2016

Buprenorphine and Rivastigmine Patch out-licensed to a multinational company in Latam

2017
2017

Built up our own manufacturing plant

2018
2018

Diclofenac sodium 1% gel developed by Amarin and approved by US FDA

2019
2019

Rivastigmine Patch: launched in Argentinean market and with successful results on a BE Study performed in Brazil

OUR TEAM

Ignacio Ketelhohn

Director

(click on name for more info)

Sergio Lucero

Director & CEO

(click on name for more info)

Francisco Stefano

Director

(click on name for more info)

Roberto Gabach

Director & New Projects Manager

(click on name for more info)

Miguel Fortuny​

Clinical Research Manager

(click on name for more info)

Germán Müller

Business Development Manager

(click on name for more info)

Julio Salvadori

Quality Manager

(click on name for more info)

Alejandro Scasso

Pharmaceutical Technology Manager

(click on name for more info)

Partner with us!

We offer expertise and experience, together with flexibility and the ability to adapt to your needs.